ADVANOMICS CORPORATION ANNOUNCES RECEIPT OF A NEW PATENT IN THE ALL-IMPORTANT FIELD OF RNA TECHNOLOGY
MONTREAL, May 25, 2011 /PRNewswire/ - Advanomics Corporation, the parent company of Sunshine Biopharma Inc. (OTCBB Symbol: SBFM), is pleased to announce that it has recently received an RNA patent in Europe (European Patent Number: 1709199). This patent positions Advanomics as a leader in the hotly pursued and very lucrative field of RNA research. Dr. Steve N. Slilaty, the inventor on this important patent, is the CEO of both Sunshine Biopharma and Advanomics Corporation. Dr. Slilaty holds four other patents issued in the United States, Europe and other countries around the world. Among Dr. Slilaty's other scientific accomplishments is the discovery of a new class of proteases called the S24 Family of Peptidases (IUBMB Enzyme Nomenclature: EC 220.127.116.11).
Advanomics's new RNA patents relates to methodology for rapid identification of all RNAs that can be made from any given piece of DNA. With this unique capability Advanomics is able to compare RNA profiles generated from Normal Tissue against Cancer Tissue and quickly identify new cancer targets for therapeutic intervention.
Advanomics Corporation is ready to license this new patent to companies interested in identifying therapeutically important RNAi molecules.
Advanomics Corporation is a privately held Canadian company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Advanomics is conducting research and development in the area of Carbon-Difluoride Chemistry to generate novel anti-cancer compounds and in the area of RNA Technology for deciphering genomic information and rapid identification of disease related molecular targets for therapeutic intervention.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
SOURCE Sunshine Biopharma Inc.